To assess the association of retinal vein occlusion (RVO) with cardiovascular and cerebrovascular mortality.
dence of 1.7%, 4 it is an important cause of moderate to severe visual loss in older persons. 5 Retinal vein occlusion frequently is associated with concomitant systemic vascular conditions. However, associations of RVO and cardiovascular or cerebrovascular diseases have not been demonstrated consistently, 3,6 -11 with most reports using clinical samples. Only the Beaver Dam Eye Study (BDES) has reported mortality associated with RVO from a populationbased sample. 3 Participants with branch RVO at baseline did not have an increased 8-year risk of dying of ischemic heart disease. 3 There have been no population-based studies of cerebrovascular mortality and RVO. In the current study, we aimed to assess the long-term (10 -12 years) vascular mortality associated with RVO using pooled data from 2 representative populations: the BDES and the Blue Mountains Eye Study (BMES) cohorts.
Patients and Methods
The BDES and BMES are 2 population-based cohort studies of vision and common eye diseases in predominantly white pop-ulations examined using similar protocols. Both were approved by the human research ethics committees in their respective institutions and were conducted adhering to tenets of the Declaration of Helsinki. The BDES examined 4926 of 5924 eligible residents aged 43 to 86 years (83.1% response) from 1988 through 1990 in Beaver Dam, Wisconsin. The BMES examined 3654 of 4433 eligible residents aged 49 years or older (82.4% response) from 1992 through 1994 in the Blue Mountains region west of Sydney, Australia.
At baseline, all participants underwent a comprehensive eye examination after pupil dilatation. Stereoscopic retinal photographs (30°) of the macula and other retinal fields of both eyes were taken using a Zeiss FF3 camera (Carl Zeiss, Oberkochen, Germany). 2, 3 Retinal photographs were available for at least 1 eye in 98% of participants (BDES, 4829/4926; BMES, 3583/3654), and complete data were available for 8378 persons (98% of 8580 seen at baseline examinations). Signs of central or branch RVO were assessed from photographs, and all cases were adjudicated by retinal specialists (RK, PM). 2, 3 Details relating to deaths were obtained from either death certificates for the BDES or the Australian National Death Index for the BMES. Causes of death were collected from death certificates and recorded using International Classification of Diseases (ICD) codes. Codes for cardiovascular death included ICD 9 (391.0 -398.9, 402.0 -402.9, 404.0 -404.9, 410.0 -429.9) and ICD 10 (I01.0 -I09.9, I11.0 -I11.9, I13.0 -I13.9, and I20.0 -I51.9), and cerebrovascular death included ICD 9 (430.0 -438.9) and ICD 10 (I60.0 -I69.9). The validity of death certificates 12 and Australian National Death Index data 13, 14 were reported previously. At baseline, systolic and diastolic blood pressures were recorded. Hypertension was defined as systolic blood pressure of 140 mmHg or more, diastolic blood pressure of 90 mmHg or more, or current self-reported use of antihypertensive medications. Current smokers were defined using interviewer-administrated questionnaires. Diabetes was defined as a previous history of diabetes or hyperglycemia, or a glycosylated hemoglobin more than 2 standard deviations above the mean for appropriate age and gender groups, or casual blood glucose level 200 mg/dl (11.1 mmol/l) or more in the BDES or fasting blood glucose 7.0 mmol/l or more in the BMES. Serum total cholesterol and high-density lipoprotein (HDL) were measured from casual (BDES) or fasting (BMES) blood specimens using standard procedures. In the BMES, primary open-angle glaucoma was diagnosed when typical glaucomatous visual field defects on the Humphrey 30-2 test (Humphrey Instruments, San Leandro, CA) were present, matching optic disc rim thinning, including an enlarged cup-to-disc ratio (Ն0.7) or cup-todisc ratio asymmetry (Ն0.3) between the 2 eyes. In the BDES, primary open-angle glaucoma was diagnosed based on 2 of the following 3 criteria: (1) visual field defect compatible with diagnosis of glaucoma; (2) cup-to-disc ratio of 0.8 or more, or difference in the ratio of 0.2 or more between the 2 eyes; 3) intraocular pressure of 22 mmHg or more.
Statistical Analysis System software (version 9; SAS Institute, Cary, NC) was used for analyses. Age-standardized mortality rates were obtained after direct age standardization of patients with RVO to the entire study population. Cox regression models estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for cardiovascular and cerebrovascular death after adjusting for age; gender; body mass index; current smoking; presence of hypertension, diabetes, and glaucoma; total cholesterol and HDL levels (per 10 mmol/l); and study site. Subgroup analyses were conducted stratified by gender and age group (Ͻ70 years and Ն70 years). Table 1 shows age-and gender-specific prevalence of RVO at baseline, plus baseline characteristics by RVO status in the 2 populations. Age-specific RVO prevalence was nearly double in the BMES compared with the BDES. Participants in both studies with baseline RVO were significantly older and were more likely to have hypertension. In the BDES, participants with RVO also were more likely to have diabetes. In the BMES, participants with RVO were more likely to report a history of angina or stroke. Prevalent glaucoma was more common in those with RVO compared with those without RVO ( Table 1) .
Results
Of 8378 participants, RVO was detected in 96 participants (1.1%) at baseline (BDES, n ϭ 38; BMES, n ϭ 58), of whom 71 had branch RVO (BDES, n ϭ 31; BMES, n ϭ 40). Over 10 to 12 years, 1312 participants (15.7%) died of cardiovascular or cardiovascular-related conditions. The cumulative cardiovascular mortality was significantly higher among participants with than without RVO at baseline (30.2% vs. 15.5%). After age standardization, mortality rates were 26.0% and 17.1% per 1000 personyears among persons with and without RVO, respectively. In participants of all ages, there was no significant difference in this mortality risk between persons with and without RVO, after adjusting for age and gender (HR, 1.2; 95% CI, 0.8 -1.7) or after further adjustment for body mass index, hypertension, diabetes, glaucoma, current smoking, and study site (HR, 1.2; 95% CI, 0.8 -1.8). In participants aged 43 to 69 years, however, RVO was associated with a 2-fold higher risk of cardiovascular mortality in a multivariable model (HR, 2.5; 95% CI, 1.2-5.2; Table 2 ). After replacing the covariable hypertension by systolic blood pressure in the multivariate regression model, the association was similar for participants aged 43 to 70 years (HR, 2.4; 95% CI, 1.1-5.2) and persisted after further adjustment for baseline history of stroke or acute myocardial infarction (HR, 2.5; 95% CI, 1.2-5.3). This association was not found among participants aged 70 years or older or in either gender subgroup of all ages (Table 2) . Similar findings were found for the individual study data, although these findings did not reach statistical significance (Table 2 ). Baseline total cholesterol was not significant in the multivariate model in either age group, whereas HDL cholesterol was significant in the model for participants aged 43 to 69 years. After further adjustment for HDL in the multivariate model, the association between RVO and mortality remained significant in participants aged 43 to 69 years (HR, 2.6; 95% CI, 1.2-5.5). The associations of branch RVO and central RVO with cardiovascular mortality in this age group were similar to those observed for any RVO (branch RVO: adjusted HR, 2.5; 95% CI, 1.1-5.6; central RVO: HR, 2.2; 95% CI, 0.3-16.2).
Over the 10 to 12 years, 341 participants (4.1%) died of cerebrovascular-related conditions. The cumulative cerebrovascular mortality was higher in participants with than without RVO at baseline (7.3% vs. 4.0%). After age standardization, mortality rates were 5.3% versus 4.5% per 1000 person-years among persons with and without RVO, respectively. There was no significant difference overall in the mortality of persons with and without RVO (multivariate adjusted HR, 1.1; 95% CI, 0.5-2.2; Table 3 ). In analyses stratified by gender, however, men with RVO at baseline had a nonsignificant, 2-fold higher risk of cerebrovascular mortality than men without RVO (HR, 2.3; 95% CI, 0.9 -5.6; Table 3 ). This association was attenuated after further adjustment for history of stroke (HR, 1.8; 95% CI, 0.7-4.5). No significant association was observed in women, or in men and women combined for those 70 years of age or older (Table 3 ). There were no cerebrovascular events among persons in the younger group (aged 43-69 years) with RVO. We were not able to analyze data by individual study because of small numbers.
Discussion
In this pooled data analysis of 2 white population-based cohorts, we found that in persons aged 43 to 69 years, the presence of RVO was associated with a 2-fold higher risk of cardiovascular mortality. Also in men, presence of RVO was associated with a nonsignificant, 2-fold higher risk of cerebrovascular mortality for all ages. These findings support an association between RVO and vascular mortality, suggested by previous clinical studies. [7] [8] [9] In our study population, glaucoma patients receiving timolol treatment had an increased risk of vascular mortality. 15 We therefore included glaucoma as a covariable in our multivariate adjusted models. The association of RVO with cardiovascular mortality in the younger subgroup seemed to be independent of other vascular risk factors and glaucoma.
The long-term prognosis of RVO was documented in the early 1970s, 10 and no overall decrease in life expectancy among patients with RVO was found, although the number of deaths resulting from vascular causes in these patients was double the national rate. A subsequent study in the 1990s also documented an association between RVO and vascular mortality. 8 A recent study using the Framingham algorithm 7 estimated higher mortality resulting from cardiovascular disease among patients with RVO. Our study provides evidence from population-based samples to support these earlier clinic-based findings.
The pathogenesis of branch and central RVO remains uncertain, but is likely multifactorial. Two different mechanisms have been postulated, that is, thrombosis in the vein resulting from compression by atherosclerotic changes in the adjacent artery and a local alteration of the blood flow resulting from unfavorable physiologic factors. The most common risk factors are increasing age, arterial hypertension, and primary open-angle glaucoma. 2, 4 In a small proportion of patients with branch RVO, retinal vasculitis may be present as a result of various relatively rare conditions such as Behçet disease, lupus, Eales disease, retinal periphlebitis, viral phlebitis, frosted branch angiitis, Takayasu arteritis, lyme borreliosis, human immunodeficiency virus, and toxoplasmosis. 16 Other more frequent systemic associations include diabetes and hypercoagulable states. 11, 17 Because the central retinal vein narrows as it traverses the lamina cribrosa, any condition that contributes to further narrowing or increases the turbulence of flow through this partial barrier may predispose a patient to thrombosis of the Ophthalmology Volume 114, Number 3, March 2007 central retinal vein. Thus, glaucoma is very frequent, particularly for central RVO. 2 The association of RVO and cardiovascular mortality among persons aged 43 to 69 years could be explained in part by the pathogenesis of RVO. Retinal vasculitis is an important cause of RVO in young adults, 18 and systemic inflammation has been found associated with all-cause or cardiovascular mortality in the elderly.
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The association of RVO and cerebrovascular mortality found in men but not in women could be explained in part by the higher risk of stroke-related mortality among men than women. 22 It is possible that the small number of patients with RVO who died of cerebrovascular causes could have led to a chance finding or a biased estimate. In these pooled population-based data, there was only 1 woman with RVO who had a stroke-related death; hence, our findings should be treated with caution.
Reasons for the higher prevalence of RVO in the BMES compared with the BDES are not entirely clear. Differences in the photographic grading of some questionable cases between the 2 studies may be responsible in part. 3 We carefully regraded all BMES cases and excluded 8 questionable cases, but the difference remained ( Table 1) . The older age range (49 -97 years in BMES vs. 43-84 years in BDES) and higher prevalence of hypertension in the BMES population are possible reasons. The age-and gender-standardized prevalence of hypertension among BMES participants was 48.7% compared with 43.6% in the BDES (PϽ0.01). 23 We cannot exclude possible differences in environmental and genetic factors between the 2 study populations.
The cross-sectional associations of RVO and baseline cardiovascular risk factors in the 2 populations were similar. The population-based nature of our samples tends to eliminate potential selection bias, whereas use of similar grading procedures in photographic documentation of RVO tends to eliminate misclassification. Although these study strengths enhance the quality of the evidence provided, small numbers in subgroup analyses limits study power, so possible chance findings cannot be excluded.
Our study may have potential implications for clinical management of patients with RVO. Although there are previous clinical reports on the systemic prognosis of RVO, available evidence regarding the risk of cardiovascular disease has been conflicting. Our study suggests that some patients with RVO may benefit from a careful cardiovascular risk assessment. However, we should emphasize that our study was not designed to address this question directly. Independent confirmation of the cardiovascular associations found in our study in larger case series is useful to determine whether routine cardiovascular risk assessments should be performed for patients with RVO.
